e-Therapeutics plc Commencement of trading on the OTCQX Best Market
RNS Number : 8190M
24 September 2021
("e-therapeutics" or the "Company")
Commencement of trading on the OTCQX Best Market in the United
Oxford, UK, 24 September 2021 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a specialist in computational drug discovery with a
focus on developing RNA interference ("RNAi") therapeutics,
announces that trading in the Company's Ordinary Shares of nominal
value of GBP0.001 each ("Ordinary Shares") will begin trading today
on the OTCQX Best Market ("OTCQX") in the United States ("U.S."),
under the ticker symbol "ETXPF".
By trading on the premium OTCQX, e-therapeutics' shares will be
available to U.S. investors during U.S. working hours and priced in
U.S. dollars and there is the potential to increase the liquidity
in e-therapeutics' shares on AIM. The OTCQX is designed for
established companies. Foreign Private Issuers, such as
e-therapeutics, that trade on the OTCQX are exempt under the U.S.
Exchange Act Rule 12g3-2(b) from SEC reporting if they make
information that is required by their home market regulator
publicly available to U.S. investors in English. e-therapeutics
will therefore face no extra reporting obligations and incur
minimal ongoing costs as a result of the Company's Ordinary Shares
being traded on the OTCQX. Through OTC Link(R) ATS and OTC Link
ECN, the OTC Market Group Inc. connects to a diverse network of
broker-dealers that provide liquidity and execution services.
B. Riley Securities acted as the Company's OTCQX sponsor.
e-therapeutics' Ordinary Shares will continue to trade on the
London Stock Exchange's AIM Market under the symbol "ETX".
Ali Mortazavi, Chief Executive Officer of e-therapeutics,
commented: "Trading on OTCQX is an important step for
e-therapeutics to broaden the Company's shareholder base. U.S.
institutional and retail investors will now be able to buy and sell
our shares via online trading platforms and mobile apps. We believe
that our computational biology and RNAi therapeutics platforms are
particularly suited to a global audience and we look forward to
sharing our equity story with an international audience."
Jonathan Dickson, Vice President at OTC Markets Group commented:
"We are delighted to welcome e-therapeutics to the OTCQX Market.
Cross-trading on OTCQX will enable e-therapeutics, listed on the
LSE AIM Market, to expand its U.S. investor base. We look forward
to providing the Company and its investors with a transparent and
efficient trading experience and all the benefits of our premium
e-therapeutics plc Tel: +44 (0)1993 883
Ali Mortazavi, CEO www.etherapeutics.co.uk
Karl Keegan, CFO
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Vadim Alexandre/Rob Rees (Corporate
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and big data with
expertise in drug discovery and development to transform the search
for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small subsets that are enriched for highly active
hits. Its proprietary platform also has novel applications in
functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
September 24, 2021 01:59 ET (05:59 GMT)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022